ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.653,67
0,92%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08365
-0,15%
Bitcoin
68.971,85
1,81%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Orchard Therapeutics PLC (ORTX)

  7. Orchard Therapeutics PLC (ORTX) News

ORTX

Orchard Therapeutics (ORTX)

Orchard Therapeutics PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ORTX
DatumZeitQuelleÜberschriftSymbolFirma
07/05/202413h00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024NASDAQ:ORTXOrchard Therapeutics PLC
03/05/202413h00GlobeNewswire Inc.Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health ListNASDAQ:ORTXOrchard Therapeutics PLC
20/03/202412h00GlobeNewswire Inc.Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic LeukodystrophyNASDAQ:ORTXOrchard Therapeutics PLC
18/03/202420h41GlobeNewswire Inc.Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.NASDAQ:ORTXOrchard Therapeutics PLC
15/02/202403h05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ORTXOrchard Therapeutics PLC
05/02/202420h39Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:ORTXOrchard Therapeutics PLC
05/02/202413h00GlobeNewswire Inc.Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler SyndromeNASDAQ:ORTXOrchard Therapeutics PLC
02/02/202413h00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposiumNASDAQ:ORTXOrchard Therapeutics PLC
31/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORTXOrchard Therapeutics PLC
31/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORTXOrchard Therapeutics PLC
25/01/202413h00GlobeNewswire Inc.Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to LibmeldyNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202423h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202423h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202423h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h41Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h39Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h37Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h35Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h34Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h30Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h25Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202411h00GlobeNewswire Inc.Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseasesNASDAQ:ORTXOrchard Therapeutics PLC
22/01/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
19/12/202322h49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
11/12/202313h00GlobeNewswire Inc.Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLDNASDAQ:ORTXOrchard Therapeutics PLC
08/12/202322h39Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ORTXOrchard Therapeutics PLC
08/12/202322h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
30/11/202322h13Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ORTXOrchard Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ORTX

Kürzlich von Ihnen besucht

USOTC
IVREF
Inovalis Real Estate Inv... (PK)
LSE
37TR
Sg Issuer 24
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten